Bond Biosciences Announces Positive Phase Ia/b Pharmacodynamic and Safety Data for BBI-001, a Novel, Non-Absorbed, Oral Therapy for Iron Overload

BBI-001 was well tolerated with no dose limiting toxicities. Single-dose administration demonstrated a statistically significant reduction of dietary iron absorption.